Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
curepeptin
- Development stage
- Preclinical
- Lead developer
- FunPep
- Modality
- Small Molecules, Peptides
01
Overview
Curepeptin is a chemically synthesized antimicrobial peptide composed of natural amino acids. It exerts its effect by disrupting bacterial cell membranes, leading to broad-spectrum antimicrobial activity. Notably, Curepeptin has demonstrated effectiveness against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Acinetobacter, and NDM-1-producing bacteria. The drug is being developed as a novel therapeutic option for infections caused by resistant pathogens[1].
- Brand names
- Curepeptin
- Other names
- Curepeptin
Beyond the preview
Go deeper on curepeptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on curepeptin.